Global Barbiturate Drugs Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Barbiturate Drugs market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Barbiturate Drugs market."
Barbiturates act as central nervous system depressants. Barbiturates are derivatives of a chemical called barbituric acid. Various barbiturate drugs are available in the market; however, all have sedative effect on the central nervous system and are clinically prescribed for anxiety. Barbiturates are also used in the treatment of epilepsy, insomnia, and status epilepticus. Barbiturate drugs are available in pill form and can be taken orally and intravenously.
Barbiturates are subjected to the Drug Abuse Prevention and Control Act in the U.S. Hence, manufacture and distribution of these drugs are strictly controlled. Barbiturate drugs act by enhancing the activity of one of the primary neurotransmitters in the brain known as gamma amino butyric acid (GABA). An increase in GABA has a sedative effect on the users brain. The effect of barbiturate lasts between 4 hours and 16 hours, depending on the type and strength of the dose.
Barbiturates become dangerous when combined with other depressants such as alcohol. There is a high risk of dependency from regular use of barbiturate drugs. This can be a physical dependency, psychological dependency, or both. The amount required for overdose varies from person to person.
North America is expected to account for the largest share of the global market from 2018 to 2025, due to highest percentage of insomnia affected patients.

The global Barbiturate Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Barbiturate Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Barbiturate Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Pfizer
    Merck
    Eli Lilly
    Mylan
    Sanofi
    Teva Pharmaceutical
    Sumitomo Dainippon Pharma
    Valeant Pharmaceuticals
    Oak Pharmaceuticals
    Meda pharmaceuticals

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    By Drug Type
        Ultra-Short Acting Barbiturate
        Short-Acting Barbiturate
        Long-Acting Barbiturate
        Combination Drugs
    By Route of Administration
        Oral
        Injectable

Segment by Application
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies